Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics Inc. develops antibody-based medicines as a clinical-stage biotechnology company. Its updates center on antibody discovery and development programs in endocrinology, women’s health, immunology, oncology, and other areas, including work on complex targets such as GPCRs and ion channels.
Recurring news themes include clinical disclosures for ABCL635, an antibody therapeutic targeting NK3R for the non-hormonal treatment of moderate-to-severe vasomotor symptoms associated with menopause. Company announcements also cover financial results, earnings-call materials, investor conference participation, platform and manufacturing updates, and patent licensing or litigation-resolution developments.
AbCellera Biologics has priced its initial public offering (IPO) at $20.00 per share, offering 24,150,000 common shares, expected to yield gross proceeds of $483 million. The IPO is set to trade on Nasdaq under the ticker 'ABCL' starting December 11, 2020, with an anticipated closing date of December 15, 2020. Should underwriters exercise their option, an additional 3,622,500 shares may be purchased. Concurrently, $90 million in convertible notes issued previously will convert at $17.00 per share, reflecting a discount to IPO price.